Last10K.com

Marina Biotech, Inc. (MRNA) SEC Filing 10-K Annual report for the fiscal year ending Wednesday, December 31, 2014

Adhera Therapeutics, Inc.

HISTORY TOOLS
CIK: 737207
Document and Entity Information (USD $)
In Millions, except Share data, unless otherwise specified
 12 Months Ended
Dec. 31, 2014
Feb. 17, 2015
Jun. 30, 2014
Document and Entity Information [Abstract]      
Entity Registrant Name Marina Biotech, Inc.    
Entity Central Index Key 0000737207    
Trading Symbol mrna    
Entity Current Reporting Status Yes    
Entity Voluntary Filers No    
Current Fiscal Year End Date --12-31    
Entity Filer Category Smaller Reporting Company    
Entity Well-known Seasoned Issuer No    
Entity Common Stock, Shares Outstanding   25,525,716dei_EntityCommonStockSharesOutstanding  
Entity Public Float     $ 14.9dei_EntityPublicFloat
Document Type 10-K    
Document Period End Date Dec. 31, 2014    
Amendment Flag false    
Document Fiscal Year Focus 2014    
Document Fiscal Period Focus FY    

View differences made from one year to another to evaluate Adhera Therapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Adhera Therapeutics, Inc..

Continue

Assess how Adhera Therapeutics, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Adhera Therapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2015 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Document And Entity Information
Consolidated Balance Sheets
Consolidated Balance Sheets (parentheticals)
Consolidated Statement Of Stockholders' Equity (deficit)
Consolidated Statement Of Stockholders' Equity (deficit) (parentheticals)
Consolidated Statements Of Cash Flows
Consolidated Statements Of Operations
Accrued Expenses
Accrued Expenses (details)
Accrued Expenses (tables)
Business, Liquidity And Summary Of Significant Accounting Policies
Business, Liquidity And Summary Of Significant Accounting Policies (detail Textuals)
Business, Liquidity And Summary Of Significant Accounting Policies (details 1)
Business, Liquidity And Summary Of Significant Accounting Policies (details 2)
Business, Liquidity And Summary Of Significant Accounting Policies (details 5)
Business, Liquidity And Summary Of Significant Accounting Policies (details)
Business, Liquidity And Summary Of Significant Accounting Policies (policies)
Business, Liquidity And Summary Of Significant Accounting Policies (tables)
Commitments And Contingencies
Commitments And Contingencies (details)
Income Taxes
Income Taxes (detail Textuals)
Income Taxes (details)
Income Taxes (tables)
Intangible Assets
Intangible Assets (detail Textuals 1)
Intangible Assets (detail Textuals)
Intellectual Property And Collaborative Agreements
Intellectual Property And Collaborative Agreements (detail Textuals 1)
Intellectual Property And Collaborative Agreements (detail Textuals)
Notes Payable
Notes Payable (detail Textuals)
Restructuring Charges
Restructuring Charges (detail Textuals)
Stock Incentive Plans
Stock Incentive Plans (detail Textuals)
Stock Incentive Plans (details Textuals 1)
Stock Incentive Plans (stock Option Activity) (details 1)
Stock Incentive Plans (stock Options Outstanding ) (details 2)
Stock Incentive Plans (stock-based Compensation Expense) (details)
Stock Incentive Plans (tables)
Stockholders' Equity
Stockholders' Equity (common Stock) (details 2)
Stockholders' Equity (details)
Stockholders' Equity (preferred Stock) (details 1)
Stockholders' Equity (tables)
Stockholders' Equity (warrants) (details 3)
Subsequent Events

Material Contracts, Statements, Certifications & more

Adhera Therapeutics, Inc. provided additional information to their SEC Filing as exhibits

Exhibit 21.1: Subsidaries Of The Registrant
Exhibit 23.1: Consents Of Experts And Counsel
Exhibit 31.1: Rule 13A-14(A)/15D-14(A) Certification
Exhibit 32.1: Section 1350 Certification
CIK: 737207
Form Type: 10-K Annual Report
Accession Number: 0001571049-15-001227
Submitted to the SEC: Tue Feb 17 2015 8:26:54 PM EST
Accepted by the SEC: Wed Feb 18 2015
Period: Wednesday, December 31, 2014
Industry: Pharmaceutical Preparations

External Resources:
SEC.gov

Bookmark the Permalink:
https://last10k.com/sec-filings/737207/0001571049-15-001227.htm